Brief Communication

Prescribing Pattern and Prescription-writing Quality of Antineoplastic Agents in the Capital City of a Middle-income Developing Country

Maryam Taghizadeh-Ghehi¹, Asiyeh Amouei², Ava Mansouri¹, Aarefeh Jafarzadeh Kohneloo¹, Molouk Hadjibabaie³,⁴

Objective: Cancer is a global health concern with growing incidence worldwide. Chemotherapy is the main treatment modality in many malignancies. This study aimed at evaluation of antineoplastic prescribing pattern and prescription-writing quality in the capital city of Iran. Methods: All dispensed chemotherapy prescriptions by four main authorized pharmacies in Tehran during 1 month were targeted. Prescriptions with no antineoplastic medications or written by specialties other than oncology-related fields were excluded from the study. From the total 10,944 eligible prescriptions, 2736 (25%) prescriptions were selected randomly for data extraction. Findings: Total 5784 antineoplastic medications were written by 239 physicians; most of them were adult hematologist-oncologist (69.0%) and male (86.6%). Each prescription contained an average of 1.8 (±0.9) antineoplastic medications. The most widely prescribed antineoplastic agents were cyclophosphamide (16.2%), fluorouracil (15.2%), doxorubicin (12.8%), and oxaliplatin (11.0%). The quality of prescription writing was poor; diagnosis, drug dosing, treatment schedule, and instructions were mostly absent. Sixty percent of drugs were written in brand names. Conclusion: The prescribing writing quality was poor and patients were at great risk of medication errors. Prompt action including policies and educational strategies should be taken to assure effective and safe patient treatment with antineoplastic medications.

Keywords: Antineoplastic agent, oncology, prescribing pattern, prescription

INTRODUCTION

Cancer is a global health concern and the third cause of death in Iran.[¹,²] Chemotherapy is the cornerstone of treatment in most of the malignancies.[³] With respect to increased number of patients who are treated in outpatient and chemotherapy clinics, the continuity of care is especially important.

In Iran, antineoplastic medications are dispensed mainly by authorized community-dwelling pharmacies. Patients should get the antineoplastic medications from these pharmacies and then return to the physician office or clinic for administration. Lack of national health information network in addition to inadequate communication between health-care providers involved in this hospital-community interface could negatively affect the efficacy and safety of chemotherapy.[⁴] The prescription plays a specifically important role in this setting as the main link between prescriber, dispenser, and the patient.

To the best of our knowledge, antineoplastic use and prescribing pattern have not been studied in Iran. Moreover, no report was published about antineoplastic prescription-writing quality in our country. This study aimed at evaluation of prescribing pattern and prescription-writing quality in the capital city of Iran.

Address for correspondence:
Dr. Molouk Hadjibabaie, E-mail: hajibaba@tums.ac.ir

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Taghizadeh-Ghehi M, Amouei A, Mansouri A, Kohneloo AJ, Hadjibabaie M. Prescribing pattern and prescription-writing quality of antineoplastic agents in the capital city of a middle-income developing country. J Res Pharm Pract 2018;7:46-50.
METHODS

All dispensed chemotherapy prescriptions by four authorized community pharmacies in Tehran from August 22, 2014, to September 22, 2014, were targeted. Prescriptions contained at least one antineoplastic medication based on the AHFS Pharmacologic-Therapeutic Classification (AHFS Drug Information 2015) were included in the study. We excluded prescriptions that were written by the physician with specialties other than oncology, hematology-oncology, radiotherapy, gynecology-oncology, and urology-oncology.

Of the 10,944 eligible prescriptions, 2736 (25%) were selected randomly. Sampling was performed using a random number list to select 25% of each day’s prescriptions, filled in each pharmacy. For each prescription, data including prescription requirements, prescribed medication(s), physician and patient characteristics, and dispensed medication(s) were recorded. The prescription-writing quality was evaluated considering the frequency of recording prescription requirements that were determined based on the WHO guide to good prescribing and Iran medical council law.⁵

Chemotherapy combinations in the prescriptions were identified, and the major indication of each combination was determined based on the Physicians’ Cancer Chemotherapy Drug Manual 2015⁶ and opinions of expert oncologist and clinical pharmacist (Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences).

Descriptive statistics were applied to explore the data. Mean (standard deviation [SD]) and frequency (percentage) were reported to describe quantitative and qualitative data. Categorical data were analyzed using Pearson’s Chi-square test; \( P < 0.05 \) was defined as a statistically significant difference. All statistical analyses were performed using SPSS version 21 (IBM SPSS Statistics, IBM Corporation, Armonk, NY, USA).

RESULTS

The selected prescriptions were written by 239 physicians and contained 5784 antineoplastic medications. Physicians’ characteristics are described in Table 1. Thirty physicians wrote approximately 50% of the prescriptions. The mean (SD) age of patients was 53.6 (16.91) years and 41.2% of them were male.

Each prescription contained an average (SD) of 4.7 (2.3) and 1.8 (0.9), total items, and antineoplastic medications, respectively. The most widely prescribed antineoplastic medications were cyclophosphamide \( (n = 443, 16.2\%) \), fluorouracil \( (n = 417, 15.2\%) \), doxorubicin \( (n = 350, 12.8\%) \), and oxaliplatin \( (n = 302, 11.0\%) \). The most frequent prescribed antineoplastic medications in patients younger than 18 years old were vincristine and methotrexate with a frequency (%) of 41 (47.1) and 24 (27.6), respectively.

Table 2 summarizes frequently prescribed (≥1%) chemotherapy combination regimens. Based on expert opinion, 14 of the 22 frequent chemotherapy regimens are mainly used in the treatment of different stages of colorectal and breast cancers.

In 41.4% of the prescriptions, R/superscription was not recorded. Diagnosis was not recorded in 92% of the prescriptions. No physician mentioned patient’s weight and/or body surface area (BSA) in the prescription. Dosing instruction was only mentioned for 9.3% of the 5780 prescribed antineoplastic items. Among them, only one dosing was written accurately (i.e., in mg/kg or mg/m²). Route of administration was only written for 1.6% of the antineoplastic medications. For >99% of the written antineoplastic medications, the number and duration of the cycle were not mentioned in the prescription.

The abbreviation was detected for names of the 16 antineoplastic medications and used in writing of 11.5% of the total prescribed antineoplastic items. Fluorouracil was the most frequent abbreviated item (453 of the 665 abbreviations). About 40.5% of the prescribed antineoplastic medications were written in the generic name. Furthermore, writing antineoplastic names in generic or brand was independent of the academic degree \( (P = 0.245) \) and specialty \( (P = 0.596) \) of the physician.

Among prescribed antineoplastic medications that were written in brand names, data regarding dispensed medication by the pharmacies were available for 2645 items. Nearly 69.9% of the dispensed medications by the pharmacies were in accordance with the prescribed brand.

### Table 1: Physicians’ characteristics

| Specialty                                | No. (%) |
|------------------------------------------|---------|
| Adult hematologist-oncologist            | 1887 (69.0) |
| Radiotherapist                           | 723 (26.4) |
| Pediatric hematologist-oncologist        | 88 (3.2) |
| Other                                    | 38 (1.4) |
| Academic degree                          |         |
| Specialist                               | 613 (22.4) |
| Post-graduate medical resident           | 23 (0.8) |
| Post-graduate medical fellow             | 83 (3.0) |
| Sub-specialist                           | 2017 (73.7) |
| Sex                                      |         |
| Male                                     | 2370 (86.6) |
| Female                                   | 366 (13.4) |
of medication. The prescribed brands and dispensed medications matched in most of the cases in three of the pharmacies, but one of the pharmacies had less matching than the rest (Pearson’s Chi-square = 399.41, \( P < 0.001 \)).

**Discussion**

The evaluation of prescribing pattern revealed that antineoplastic medications are mainly prescribed by hematologist–oncologists, and the type of mostly prescribed medications is compatible with the prevalent cancer types in our country.\(^7\)

An average of 1.8 antineoplastic medications was written in the prescriptions. Similarly, an average number of 1.97 and 1.78 cytotoxic medications per prescription was reported in the institutional studies in India and Nepal, respectively.\(^8,9\)

Sixty-three percent of the detected chemotherapy regimens are mainly used in the treatment of different stages of the breast and colorectal cancers. It is in agreement with the GLOBOCAN report that mentioned breast cancer to have the highest age-adjusted incidence in Iran.\(^7\) Moreover, institutional studies in India also reported fluorouracil and platinum combination as the most frequently used chemotherapy.\(^9\) Similarly, pyrimidine analogs (for example, cytarabine, fluorouracil, gemcitabine, capecitabine, and tegafur) were also the most frequently used antineoplastic medications in Taiwan.\(^10\)

The quality of prescription writing in the studied antineoplastic prescriptions was unacceptable. Diagnosis was written only in 8% of the prescriptions. Weight and/or BSA of the patient were not written in any prescription. The dosing instruction and route of administration of antineoplastic medication were mentioned for <10% of the prescribed items, and nearly, all of them had no information regarding the treatment cycle duration and intervals.

We could not find any published study regarding antineoplastic medication prescribing quality and pattern in Iran. Scant data are available about commitment to prescription-writing principles in Iran. In a study in Kashan, dosing instructions were written in 47% of the prescribed items and weight of the patient was available in 0.6% of prescriptions.\(^11\)

The physicians might assume it unnecessary to write instructions for antineoplastic agents when the patient should return for administration after filling the prescription. However, lack of dosing and administration instruction in the prescriptions could easily result in medication error that would be fatal for antineoplastic medications. Moreover, the clinical verification of the antineoplastic prescription by the pharmacist could not be performed when no data are

| Table 2: Chemotherapy combination regimens with frequency of ≥1% in the prescriptions |
|---------------------------------|---------------------------------|
| (%)                             | Chemotherapy combination        | Assumed Diagnosis                                      |
| 9.0                             | Fluorouracil + Oxaliplatin      | Metastatic colorectal/colorectal cancer                 |
| 8.6                             | Doxorubicin + Cyclophosphamide  | Breast cancer                                           |
| 4.5                             | Carboplatin + Paclitaxel        | Metastatic breast cancer                                |
| 4.1                             | Cisplatin + Fluorouracil + Docetaxel | Head and neck cancer                   |
| 3.8                             | Capecitabim + Oxaliplatin       | Colorectal cancer                                      |
| 2.7                             | Doxorubicin + Cyclophosphamide + Vincristine + Rituximab | Gastric cancer/DLBCL                                  |
| 2.3                             | Bleomycin + Dacarbazine + Vinblastin + Doxorubicin | Hodgkin lymphoma                                      |
| 2.0                             | Docetaxel + Cyclophosphamide    | Breast cancer                                           |
| 1.8                             | Epirubicin + Cyclophosphamide   | Breast cancer                                           |
| 1.8                             | Gemcitabine + Oxaliplatin       | Biliary tract/Hepatocellular cancer                    |
| 1.8                             | Docetaxel + Cyclophosphamide + Doxorubicin | Breast cancer                                     |
| 1.7                             | Fluorouracil + Methotrexate + Cyclophosphamide | Breast cancer                                   |
| 1.6                             | Gemcitabine + Vinorelbine       | NSCLC                                                  |
| 1.6                             | Tamoxifen + Triptorelin         | Breast cancer                                           |
| 1.3                             | Carboplatin + Docetaxel         | Advanced NSCLC                                          |
| 1.2                             | Bevacizumab + Irinotecan + Fluorouracil | Metastatic colorectal cancer                    |
| 1.2                             | Carboplatin + Gemcitabine       | Metastatic NSCLC/bladder cancer                        |
| 1.1                             | Fluorouracil + Irinotecan       | Metastatic colorectal cancer                          |
| 1.1                             | Epirubicin + Cyclophosphamide + Fluorouracil | Breast cancer                                   |
| 1.0                             | Bevacizumab + Oxaliplatin + Fluorouracil | Advanced colorectal cancer                   |
| 1.0                             | Bortezomib + Cyclophosphamide   | Multiple myeloma                                       |
| 1.0                             | Cetuximab + Oxaliplatin         | Metastatic colorectal cancer                          |

DLBCL=Diffuse Large B-Cell Lymphoma, NSCLC=Non-small-cell lung carcinoma
recorded regarding diagnosis, patient weight or BSA, dosing, administration instruction, and treatment schedule. This is while the verification is a main recommended strategy to prevent chemotherapy prescription errors.[12] In addition, writing dosing and use instructions and chemotherapy schedule is especially important for oral antineoplastic medications.[4] In our country, the prescription sheets of insurance companies do not have a specified part for recording patient’s weight and/or BSA. The prescription sheets of most of the insurance companies have a section for writing the diagnosis. However, there is no obligation prohibits filling prescriptions that do not contain the diagnosis.

In spite of recommendations to use generic names (not brand names) and avoiding abbreviations in prescribing,[12] more than half of the antineoplastic medications were written in brand names in our study. In addition, writing fluorouracil in abbreviation occurred frequently in studied prescriptions. Specific notifications have been released to avoid writing fluorouracil in abbreviation, considering reported incidents and medication errors. Physicians usually emphasize on getting a specific brand medication, concerning efficacy and safety of the less popular brand and generic medications. Nearly 70% of the written and dispensed brand antineoplastic medications were compatible in our study.

One of the study limitations is restriction of prescription inclusion to the main pharmacies in Tehran. However, pharmacies with major share of antineoplastic medication dispensing in Tehran were considered as the study setting while distribution of cancer treatment services in the country is discriminate, and chemotherapy facilities are concentrated in the capital city.[12] Another limitation is short duration of study that could affect the comprehensiveness of the observation.

This study could provide a snapshot about antineoplastic prescribing pattern in Iran. The prescription-writing quality was unacceptable that puts patients at risk of medication errors. Prompt action including policies and educational strategies should be taken to assure effective and safe patient treatment with antineoplastic medications.

**Authors’ Contribution**

Concept: Molouk Hadijibabaie, Design: Molouk Hadijibabaie, Maryam Taghizadeh-Ghehi, Definition of intellectual content: Molouk Hadijibabaie, Maryam Taghizadeh-Ghehi, Ava Mansouri, Literature search: Maryam Taghizadeh-Ghehi, Data acquisition: Asiyeh Amouei, Data analysis: Maryam Taghizadeh-Ghehi, Ava Mansouri, Asiyeh Amouei, Statistical analysis: Arefeh Jafarzadeh Kohneloo, Manuscript preparation: Maryam Taghizadeh-Ghehi, Asiyeh Amouei, Manuscript editing and manuscript review: Ava Mansouri, Arefeh Jafarzadeh Kohneloo.

**Acknowledgments**

We would like to thank Dr. F. Shahi, Dr. Z. Jahangard-Rafsanjani, Dr. S. Tasharoei, Dr. S. Javidi, Dr. Z. Khajehpiri, Dr. L. Ghaffari, Dr. F. Mohammadpour, Dr. K. Heidari, and Ms. S. Afjehei for their efforts and collaborations in the study. This study was supported by the Research Council of Tehran University of Medical Sciences (grant number: 93-02-156-26370).

**Financial support and sponsorship**

This study was financially supported by the Research Council of Tehran University of Medical Sciences (grant number: 93-02-156-26370).

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Modriyan M, Rahimzadeh S, Cheraghi Z, Saeedi Moghaddam S, Rezaei N, Tohidinik HR, et al. Burden of cancers in Iran from 1990 to 2010: Findings from the Global Burden of Disease study 2010. Arch Iran Med 2015;18:629-37.

2. Rassouli M, Sajjadi M. Cancer care in countries in transition: The Islamic republic of Iran. In: Silbermann M, editor. Cancer Care in Countries and Societies in Transition: Individualized Care in Focus. Cham, Switzerland: Springer International Publishing; 2016. p. 317-36.

3. van der Schueren E, Horiot JC, Leunens G, Rubens R, Steward W, van Dongen JA, et al. Quality assurance in cancer treatment. Report of a Working Party from the European School of Oncology. Eur J Cancer 1993;29A: 172-81.

4. Hammond L, Marsden E, O’Hanlon N, King F, Henman MC, Keane C, et al. Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland. Int J Clin Pharm 2012;34:893-901.

5. de Vries T, Henning RH, Hogerzeil H, Fresle D. Guide to Good Prescribing. Geneva: World Health Organization; 1994. p. 134.

6. Edward Chu VT, editor. Physicians’ Cancer Chemotherapy Drug Manual. 15th ed. Burlington, MA, USA: Jones & Bartlett Learning; 2015.

7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan. iarc.fr. [Last accessed on 2017 Aug 15].

8. Khan GM, Thapa RK, Adhikari DS, Rajbhandari M, Dwa P, Shrestha S, et al. Evaluation of cancer prevalence and cytotoxic medication prescribing in central region of Nepal. Kathmandu Univ J Sci Eng Technol 2013;9:189-99.

9. Mugada V, Paruchuri A, Munagala M. Drug utilization evaluation of anticancer drugs in a tertiary care teaching
hospital: A descriptive observational study. J Appl Pharm Sci 2016;6:098-101.

10. Hsu JC, Lu CY. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: A retrospective observational study. BMJ Open 2016;6:e011322.

11. Rangraz Jeddi M, Rangraz Jeddi F, Rezaei Mofrad MR. Physicians’ commitment to principles of prescription writing for outpatients insured by Medical Services Insurance Organization in Kashan. Health Inf Manage 2011;8:338.

12. Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol 2010;6:220-37.